J 2022

Health and economic impact of subcutaneous allergen immunotherapy in patients with pollen-induced allergic rhinoconjunctivitis: real-word evidence from the Czech Republic

TURKOVA, Barbora, Jan TUZIL, Barbora PILNACKOVA, Helena DOLEZALOVA, Daniela STROSOVA et. al.

Základní údaje

Originální název

Health and economic impact of subcutaneous allergen immunotherapy in patients with pollen-induced allergic rhinoconjunctivitis: real-word evidence from the Czech Republic

Autoři

TURKOVA, Barbora (203 Česká republika), Jan TUZIL (203 Česká republika, garant), Barbora PILNACKOVA (203 Česká republika), Helena DOLEZALOVA (203 Česká republika), Daniela STROSOVA (203 Česká republika), Vit PETRU (203 Česká republika), Ester SEBEROVA (203 Česká republika) a Tomáš DOLEŽAL (203 Česká republika, domácí)

Vydání

IMMUNOTHERAPY, London, FUTURE MEDICINE LTD, 2022, 1750-743X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30102 Immunology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.800

Kód RIV

RIV/00216224:14110/22:00128329

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

000853009100001

Klíčová slova anglicky

allergy; costs; economics; effectiveness; immunotherapy; pollen; rhinitis; rhinoconjunctivis; savings; subcutaneous

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 27. 1. 2023 13:49, Mgr. Tereza Miškechová

Anotace

V originále

Plain language summary Hay fever has become more frequent over the years, and allergen immunotherapy (AIT) remains the only treatment able to reduce both symptoms and the root cause of this condition. However, it is not clear whether the benefits outweigh the price of the therapy. In this study, we observed patients in the common practice and described the effectiveness, safety and costs of injected AIT for pollen-induced hay fever. Of 471 new AIT users, 317 completed three courses of treatment in 3 consecutive years. Symptoms improved in 96% of them; no serious adverse reactions were reported. The cost of symptom-relieving medication decreased by 49% and the cost of unscheduled physician visits decreased by 73%. Except for costs related to AIT administration, total healthcare costs decreased by 54% compared with the years before AIT. In clinical practice, injected AIT is an effective treatment which generates savings on other medication and unscheduled physician consultations. Tweetable abstract In Czech clinical practice, subcutaneous allergen immunotherapy is an effective treatment for allergic rhinoconjunctivitis, generating savings on symptomatic medication and unscheduled physician consultations. Background: The prevalence of allergic rhinoconjunctivitis (AR) has been increasing over the years, and allergen immunotherapy (AIT) remains the only disease-modifying treatment. However, cost-effectiveness data remain scarce. Methods: In this single-arm, noninterventional, prospective, multicenter study, we describe the effectiveness, safety and costs of subcutaneous AIT for pollen-induced allergic rhinoconjunctivitis. Results: Of 471 new AIT users, 317 completed three courses of treatment, and symptoms improved in 96%; no serious adverse reactions were reported. The cost of symptomatic medication decreased by 49% and the cost of unscheduled specialist visits decreased by 73%. Except for AIT administration, total healthcare costs decreased by 54% compared with the baseline pollen season without AIT. Conclusion: In clinical practice, subcutaneous AIT is an effective treatment generating savings on symptomatic medication and unscheduled consultations.